Title

Evaluation of Low Dose Valganciclovir for the Prevention of Cytomegalovirus in Liver Transplant Recipients

Document Type

Poster Presentation

Publication Date

4-30-2017

Abstract

Cytomegalovirus (CMV) causes significant morbidity and mortality following orthotopic liver transplantation (OLT). Valganciclovir (VGCV) is used to prevent CMV, but at labeled doses can cause hematologic toxicities. Prior studies in OLT have demonstrated comparable efficacy of low dose (LD)-VGCV to oral ganciclovir, but the efficacy of LD-VGCV compared to standard dose (SD) VGCV has not been established. Herein we describe the first report comparing LD-VGCV to SD-VGCV for the prevention of CMV in OLT.

DOI

https://doi.org/10.1111/ajt.14306

Comments

Poster presented at the 2017 American Transplant Congress (ATC) in Chicago, Illinois, April 30 2017.

Abstract published in the American Journal of Transplantation Volume 17, Issue S3 Special Issue: 2017 American Transplant Congress Abstracts: https://doi.org/10.1111/ajt.14306

Abstract also available on the conference website.

Additional Files

Share

COinS